Zymeworks

Zymeworks is a royalty-driven biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases. The company's healthcare asset aggregation strategy focuses on optimizing future cash flows from an emerging licensed product portfolio, including Ziihera (zanidatamab-hrii), pasritamig, and other licensed products and product candidates.

Zymeworks operates with a disciplined approach to investing, leveraging its proprietary complementary therapeutic platforms and fully integrated drug development engine to precisely engineer and develop highly differentiated multifunctional antibody-based therapeutics. The company's product candidates utilize multiple novel targets and address indications representing significant unmet medical need, particularly in oncology. Zanidatamab and pasritamig are currently being investigated in over 15 clinical trials across solid tumor indications.

With over 10 years of protein engineering and bispecific development experience, Zymeworks has developed 9 proprietary platforms providing the foundation for its innovative pipeline. The company's platforms have been further leveraged and clinically validated through strategic partnerships with global biopharmaceutical companies. Zymeworks maintains global operations with sites in Vancouver (headquarters), Bellevue (Washington), Dublin (Ireland), and Singapore.